Pay in 4 interest-free payments of $7.47 Learn more
Ships within 48 hours · Estimated delivery Aug 11 - Aug 16
Primary concerns include additive cardiovascular effects (tachycardia, hypertension), intensified gastrointestinal symptoms (nausea, vomiting, constipation), central nervous system effects (insomnia, anxiety), and excessive appetite suppression potentially leading to nutritional deficiencies
Nebulised/inhaled mainly respiratory, not for skin
No, like this is a big giant debilitating disease that needs to be taken seriously and we don't need to be minimizing people suffering from it and making them feel like they shouldn't take medication because of it
I can already see the result
2020;12(6):e8860
All in-text citations in brackets (e.g., (Biomed Industries. News- Press Release-Announces Positive Phase I Results of Oral Quadruple Receptor Agonist NA-931 for Obesity Treatment .)) correspond to source materials that substantiate the preceding statements.
